var data={"title":"Nitisinone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nitisinone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6656?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nitisinone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nitisinone: Patient drug information&quot;</a> and <a href=\"topic.htm?path=nitisinone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Nitisinone: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201700\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Nityr;</li>\n      <li>Orfadin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201713\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        4-Hydroxyphenylpyruvate Dioxygenase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201701\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Must be used in conjunction with a diet restricted in tyrosine and phenylalanine. Titrate dose as needed based on biochemical and/or clinical response. If the biochemical response is satisfactory, the dosage should be adjusted only according to body weight gain. Do not adjust dose according to plasma tyrosine concentration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hereditary tyrosinemia type 1 (HT-1):</b> Oral: Initial: 0.5 mg/kg twice daily. Increase to 0.75 mg/kg twice daily if succinylacetone is detectable 4 weeks after initiation. Further increase may be needed based on the evaluation of all biochemical parameters (maximum dose: 2 mg/kg/day); dose may be administered once daily (eg, 1 to 2 mg/kg once daily) if serum and urine succinylacetone is undetectable after &ge;4 weeks of therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201708\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=nitisinone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Nitisinone: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Must be used in conjunction with a diet restricted in tyrosine and phenylalanine. Titrate dose as needed based on biochemical and/or clinical response. If the biochemical response is satisfactory, the dosage should be adjusted only according to body weight gain. Do not adjust dose according to plasma tyrosine concentration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hereditary tyrosinemia type 1 (HT-1):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;5 years: Initial: 0.5 mg/kg twice daily. Increase to 0.75 mg/kg twice daily if succinylacetone is detectable 4 weeks after initiation. Further increase may be needed based on the evaluation of all biochemical parameters (maximum dose: 1 mg/kg twice daily).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;5 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201702\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20210498\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20210499\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201683\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Orfadin: 2 mg, 5 mg, 10 mg, 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Orfadin: 4 mg/mL (90 mL) [contains polysorbate 80, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nityr: 2 mg, 5 mg, 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201670\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11234123\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Distributed by Orfadin4U comprehensive patient support program.  Information regarding acquisition of product may be obtained by calling 877-473-3179. Additional information can be found at http://www.orfadin.com</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201685\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsules: Administer at least 1 hour prior to, or 2 hours after a meal. Capsules may be opened and contents suspended in a small quantity of water, formula, or apple sauce; administer immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension: Administer without regards to meals. Allow suspension to warm to room temperature (30 to 60 minutes) prior to preparation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Administer without regards to meals. Tablets may be disintegrated in water and administered using an oral syringe or crushed and mixed with applesauce (administration with other liquids or foods is not recommended [has not been studied]). Refer to manufacturer's labeling for detailed instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201684\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hereditary tyrosinemia type 1:</b> Treatment of hereditary tyrosinemia type 1 (HT-1) as an adjunct to dietary restriction of tyrosine and phenylalanine in adult and pediatric patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201675\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Increased plasma tyrosine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Alopecia (1%), exfoliative dermatitis (1%), maculopapular rash (1%), pruritus (1%), xeroderma (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Porphyria (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Leukopenia (3%), thrombocytopenia (3%), granulocytopenia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Hepatic failure (7%), hepatic neoplasm (malignant: 5%; benign: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Conjunctivitis (2%), corneal opacity (2%), keratitis (2%), photophobia (2%), blepharitis (1%), cataract (1%),  eye pain (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Epistaxis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, brain disease, brain neoplasm, bronchitis, corneal ulcer, cyanosis, diarrhea, enanthema, gastric distress, gastrointestinal hemorrhage, headache, hepatomegaly, hyperkinesia, hypoglycemia, increased liver enzymes, melena, seizure, septicemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201688\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to nitisinone or any component of the formulation; breastfeeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201673\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic effects: Failure to adequately restrict dietary tyrosine and phenylalanine may lead to hyperkeratotic plaques on the soles and palms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Leukopenia and/or thrombocytopenia have been reported; may improve with dose reduction. May be due to underlying liver disease rather than drug-related (McKiernan 2006). Monitor platelets and WBC regularly during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurological effects: Failure to adequately restrict dietary tyrosine and phenylalanine may lead to variable degrees of intellectual disability and developmental delay; clinical laboratory assessment including tyrosine levels is recommended for any patient exhibiting abrupt changes in neurological status while on therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: Failure to adequately restrict dietary tyrosine and phenylalanine may lead to ocular toxicities (eg, conjunctivitis, corneal ulcers, corneal opacities, eye pain, keratitis, photophobia). Slit-lamp examination of the eyes is recommended prior to initiation of therapy and in patients who develop photophobia, eye pain, or signs of inflammation (eg, redness, swelling, burning of the eyes). Immediate measurement of plasma tyrosine concentration is also recommended in patients who develop ocular symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glycerol: Oral suspension contains 500 mg/mL of glycerol; oral doses of glycerol &ge;10 g may cause headache, upset stomach, and diarrhea. Patients receiving single doses &gt;20 mL are at increased risk for these adverse reactions; consider switching patients unable to tolerate the oral suspension to nitisinone capsules.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dietary restrictions: Must be used with dietary restriction of tyrosine and phenylalanine; inadequate restriction can result in toxic effects to the eyes, skin, and nervous system. Evaluate plasma tyrosine concentrations in patients who develop signs and symptoms of toxicity. Nutritional consultation is recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299764\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6221931\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10149&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201697\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Effect of taking nitisinone capsules with food is unknown; administration of oral suspension with a high calorie and high fat meal decreased C<sub>max</sub> by ~20%, but did not affect AUC. Tyrosine toxicity can occur without proper dietary restriction of tyrosine and phenylalanine. Management: Administer capsules at least 1 hour prior to, or 2 hours after a meal; administer oral suspension without regard to meals. Dietary restriction of tyrosine and phenylalanine is required. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201690\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20617178\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if nitisinone is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of exposure to the infant, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201691\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Nitisinone capsules should be taken at least 1 hour prior to, or 2 hours after a meal. Dietary restriction of tyrosine and phenylalanine is required.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201680\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dietary tyrosine and phenylalanine (assess dietary intake with tyrosine concentrations &gt;500 micromole/L); urine and/or plasma succinylacetone, liver function parameters, and alpha-fetoprotein levels (in addition, at initiation or if there is a deterioration of the patient's clinical condition, may also monitor urine 5-aminolevulinate and erythrocyte porphobilinogen-synthase activity); body weight; slit-lamp examination (prior to initiation of therapy and in patients who develop symptoms of ocular toxicity); plasma tyrosine (as clinically indicated with side effects; concentrations should be kept &lt;500 micromole/L to avoid toxicity); platelet and white blood cell counts (regularly during therapy).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Plasma succinylacetone may take up to 3 months to normalize after start of therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201672\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">In patients with HT-1, tyrosine metabolism is interrupted due to a lack of the enzyme (fumarylacetoacetate hydrolase) needed in the last step of tyrosine degradation. Toxic metabolites of tyrosine accumulate and cause liver and kidney toxicity. Nitisinone competitively inhibits 4-hydroxyphenyl-pyruvate dioxygenase, an enzyme present early in the tyrosine degradation pathway, thereby preventing the build-up of the toxic metabolites. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201687\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Limited pharmacokinetic studies exist for children or HT-1 patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">V<sub>d</sub>: Healthy volunteers: 8.2 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &gt;95%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Minor metabolism possibly via CYP3A4</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Healthy volunteers: Terminal half-life: Capsule, suspension: 54 hours; Tablet: 59.3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Healthy volunteers: Capsule: 3.5 hours (range: 0.8 to 8 hours); Suspension: 0.4 hours (range: 0.2 to 4 hours); Tablet: 3.5 hours (range: 1 to 4 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Healthy volunteers: Urine (Hall 2001)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323495\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Orfadin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (60): $6,539.27</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (60): $16,348.07</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (60): $32,696.17</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (60): $65,392.33</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Orfadin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/mL (90 mL): $21,382.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Nityr Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (60): $5,884.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (60): $14,713.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (60): $29,425.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038706\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Orfadin (AT, AU, BB, BE, BG, BM, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, HR, IE, IL, IT, JP, KR, LT, LV, MT, NL, NO, PL, PT, RO, RU, SE, SI, SK, TR, TW);</li>\n      <li>Orfadyn (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Hall MG, Wilks MF, Provan WM, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and Mesotrione, Inhibitors of 4-Hydroxyphenyl Pyruvate Dioxygenase (HPPD) Following a Single Dose to Healthy Male Volunteers,&rdquo; <i>Br J Clin Pharmacol</i>, 2001, 52(2):169-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitisinone-drug-information/abstract-text/11488774/pubmed\" target=\"_blank\" id=\"11488774\">11488774</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holme E and Lindstedt S, &ldquo;Nontransplant Treatment of Tyrosinemia,&rdquo; <i>Clin Liver Dis</i>, 2000, 4(4):805-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitisinone-drug-information/abstract-text/11232358/pubmed\" target=\"_blank\" id=\"11232358\">11232358</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindstedt S, Holme E, Lock EA, et al, &ldquo;Treatment of Hereditary Tyrosinaemia Type 1 by Inhibition of 4-Hydroxyphenylpyruvate Dioxygenase,&rdquo; <i>Lancet</i>, 1992, 340(8823):813-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitisinone-drug-information/abstract-text/1383656/pubmed\" target=\"_blank\" id=\"1383656\">1383656</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McKiernan PJ, &ldquo;Nitisinone in the Treatment of Hereditary Tyrosinaemia Type 1,&rdquo; <i>Drugs</i>, 2006, 66(6):743-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitisinone-drug-information/abstract-text/16706549/pubmed\" target=\"_blank\" id=\"16706549\">16706549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nityr (nitisinone) [prescribing information]. Cambridge, UK: Cycle Pharmaceuticals; July 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitisinone-drug-information/abstract-text/16706549/pubmed\" target=\"_blank\" id=\"16706549\">16706549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Orfadin (nitisinone) [prescribing information]. Waltham, MA: Sobi Inc; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Orfadin (nitisinone) [Canadian product monograph]. Stockholm, Sweden: Swedish Orphan Biovitrum AB; November 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10149 Version 112.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F201700\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F201713\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F201701\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F201708\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F201702\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F20210498\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20210499\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F201683\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F201670\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11234123\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F201685\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F201684\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F201675\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F201688\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F201673\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299764\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6221931\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F201697\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F201690\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20617178\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F201691\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F201680\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F201672\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F201687\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323495\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038706\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10149|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nitisinone-patient-drug-information\" class=\"drug drug_patient\">Nitisinone: Patient drug information</a></li><li><a href=\"topic.htm?path=nitisinone-pediatric-drug-information\" class=\"drug drug_pediatric\">Nitisinone: Pediatric drug information</a></li></ul></div></div>","javascript":null}